Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

NCT04320602 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

BIOLOGICAL: Eculizumab
BIOLOGICAL: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.